RecruitingPhase 1NCT07086105

A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma

Studying Neuroendocrine neoplasm

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Adze Biotechnology Australia Pty Ltd
Intervention
Adze1.C(drug)
Enrollment
30 target
Eligibility
18 years · All sexes
Timeline
20252027

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07086105 on ClinicalTrials.gov

Other trials for Neuroendocrine neoplasm

Additional recruiting or active studies for the same condition.

See all trials for Neuroendocrine neoplasm

← Back to all trials